Neuropace
NPCE
41 hedge funds and large institutions have $131M invested in Neuropace in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 1 closing their positions.
1,700% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 1
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
64% more funds holding
Funds holding: 25 → 41 (+16)
21.6% less ownership
Funds ownership: 69.89% → 48.29% (-22%)
26% less capital invested
Capital invested by funds: $176M → $131M (-$45M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$770K |
| 2 |
Renaissance Technologies
New York
|
+$511K |
| 3 |
Morgan Stanley
New York
|
+$486K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$337K |
| 5 |
Jane Street
New York
|
+$294K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.9M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$602K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$369K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$263K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$209K |
NPCE Hedge Fund Activity: Q4 2023 in Review
41 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2023, worth a combined $131M — down 26% from $176M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NPCE positions and 1 closed out — a net gain of 17 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Kent Lake Capital, adding an estimated $770K. The largest seller was Fidelity Investments, cutting an estimated $1.9M.
- 41 institutional investors held Neuropace (NPCE) as of Q4 2023, up from 25 in Q3 2023.
- Funds reported $131M of Neuropace stock for Q4 2023, down 26% quarter-over-quarter.
- 18 funds opened new Neuropace positions in Q4 2023 and 1 closed out, a net change of +17 holders.
- The largest Neuropace buyer in Q4 2023 was Kent Lake Capital, an estimated $770K added.
- The largest Neuropace seller in Q4 2023 was Fidelity Investments, an estimated $1.9M sold.
Based on aggregated 13F filings for Q4 2023.